文献速递膀胱癌与上尿路尿路上皮癌

膀胱癌特异性健康相关生活质量量表的比较评估

Comparative Evaluation of Bladder-specific Health-related Quality of Life Instruments for Bladder Cancer.
PubMed 文献 · Urology · 2017-07-10

该横断面研究比较了FACT-VCI与BCI两种膀胱癌特异性生活质量量表在131例根治性膀胱切除术后患者中的表现,问卷回应率为49%(回肠通道31例、原位新膀胱33例)。两量表总体相关性中等(r=0.57,P<.001),BCI尿功能评分在回肠通道组显著更优(P=.002),而FACT-VCI未显示组间差异。作者认为BCI更适于评估和咨询不同尿流改道后的治疗特异性变化。

要点

  • FACT-VCI与BCI总体相关性中等(r=0.57,P<.001),但捕捉不同生活质量维度。
  • BCI尿功能评分回肠通道组显著优于原位新膀胱组(P=.002)。
  • FACT-VCI在两种尿流改道间未发现显著差异。

核心结论

  • FACT-VCI与BCI在同一患者队列中相关性良好,但捕捉不同的健康相关生活质量方面。
  • 作者认为BCI因专注于膀胱癌治疗相关问题,是评估和咨询尿流改道后治疗特异性变化的更好工具。

研究设计与样本

  • 横断面研究,2009年至2014年接受根治性膀胱切除术的256例患者中131例符合纳入和排除标准。
  • 将FACT-VCI和BCI问卷邮寄给这些患者,采用Spearman相关系数比较两量表总体及各领域评分,采用非参数Wilcoxon秩和检验按尿流改道类型比较生活质量评分。

主要发现

  • 研究回应率为49%,包括回肠通道31例和原位新膀胱33例。
  • FACT-VCI与BCI问卷总体相关性中等(r=0.57,P<.001)。
  • BCI各领域评分与FACT-VCI膀胱癌特异性领域评分强相关(r=0.74,P<.001)。
  • BCI尿功能评分回肠通道组显著优于原位新膀胱组(P=.002)。
  • FACT-VCI在回肠通道组与原位新膀胱组之间未发现显著差异。

关键数值与推荐

  • FACT-VCI与BCI总体Spearman相关系数r=0.57(P<.001)。
  • BCI各领域与FACT-VCI膀胱癌特异性领域Spearman相关系数r=0.74(P<.001)。
  • BCI尿功能评分回肠通道组vs原位新膀胱组P=.002。

临床怎么用

  • 作者认为BCI是评估和咨询尿流改道后治疗特异性变化的更好工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare 2 bladder cancer-specific health-related quality of life instruments (HRQOL) in the same patient population. Previous HRQOL studies in cystectomy patients have yielded conflicting results. Using a cross-sectional study design, we examined the only 2 validated bladder cancer-specific (HRQOL) measures. METHODS: Of the 256 patients who had undergone radical cystectomy from 2009 to 2014, 131 met both inclusion and exclusion criteria. The Functional Assessment Cancer Therapy-Vanderbilt Cystectomy Index (FACT-VCI) and Bladder Cancer Index (BCI) were mailed to these patients. Overall HRQOL and individual domain scores were compared between the 2 instruments with a Spearman correlation coefficient. HRQOL scores were compared by urinary diversion type as well using a non-parametric Wilcoxon rank sum test. RESULTS: Our study had a response rate of 49% from 31 ileal conduit (IC) and 33 orthotopic neobladder patients. Overall, there was a moderate correlation between the FACT-VCI and BCI surveys (r = 0.57, P <.001). Responses on the BCI domains were strongly correlated with responses on the bladder cancer-specific domain of the FACT-VCI (r = 0.74, P <.001). The BCI scores for urinary function were significantly better in the IC group (P = .002). No significant difference was found between IC and orthotopic neobladder using the FACT-VCI. CONCLUSION: The FACT-VCI and BCI instruments correlate well within the same patient cohort but capture different aspects of HRQOL. By focusing exclusively on bladder cancer treatment concerns, the BCI appears to be a better tool for assessing and counseling patients on expected treatment-specific changes after diversion type.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Moncrief TJ, Balaji P, Lindgren BB, et al. Comparative Evaluation of Bladder-specific Health-related Quality of Life Instruments for Bladder Cancer. Urology. 2017. PMID: 28705577. doi:10.1016/j.urology.2017.06.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。